chevron_leftBack
As of 24 April 2025, Inventiva S.A. has a market cap of $350.53M USD, ranking #14040 globally and #207 in France. It ranks #1385 in the Healthcare sector, and #378 in the Biotechnology industry.
Key Stats
Market Cap
$350.53MUSD
308.03M EUR
Enterprise Value
$444.65MUSD
392.37M EUR
Revenue (TTM)
$16.04MUSD
14.09M EUR
EBITDA (TTM)
-$106.26MUSD
-93.76M EUR
Net Income (TTM)
-$209.62MUSD
-184.21M EUR
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Frederic Cren
open_in_new
Employees
118
Founded
2011
Website
inventivapharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.6% | 13% | 17% | 53% | 22% | 1.9% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
IVA
Inventiva SA
ISIN: FR0013233012
Shares Out.:
Shares Outstanding:
95.488M1
Shares Float:
60.882M2
|
3.17 EUR | |
|
0RNK
Inventiva SA
ISIN: FR0013233012
|
3.23 EUR | |
|
NASDAQ
MIC: XNAS
|
IVA
Inventiva SA ADR
ISIN: US46124U1079
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
3.91 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of MASH and other diseases in France, the United States, and Internationally. It develops Lanifibranor, for the treatment of patients with metabolic dysfunction-associated steatohepatitis, a progressive, chronic liver disease, which is in Phase III clinical trial; and Odiparcil for the treatment of patients with mucopolysaccharidoses, or MPS, a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was incorporated in 2011 and is headquartered in Daix, France.
